Nexstim Plc announced that it has received an order for two NBS 6 therapy systems from a clinic customer located in the Western United States.
The NBS 6 represents the latest generation of Nexstim's product line, designed to significantly enhance usability and performance. The system is FDA-cleared for the treatment of major depressive disorder (MDD), offering advanced therapeutic capabilities for patients.
Nexstim's technology is built on its proprietary navigated transcranial magnetic stimulation (nTMS) platform, which provides precise and effective treatment solutions. The introduction of the NBS 6 marks another step forward in delivering innovative, patient-focused therapies to the global healthcare market.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.